FSD Pharma

FSD Pharma earns a Neutral rating with 3/5 conviction, reflecting a composite score near 40 and an uneven pillar profile. Regulatory is the strongest contribution in the upper 40s, supported by an 80 enforcement subscore and a jurisdiction score of 50. Market contributes 40 despite unavailable quotation data, while fundamentals rank in the upper 30s and constrain upside. Editorial is weakest at 30, consistent with no recorded newsroom or brief activity. The combination produces a balanced rating band rather than a directional call, with regulatory standing offset by stretched financial condition, limited market visibility, and sparse coverage.

Fundamentals remain pressured. Revenue contracted 7.4% year over year, producing a revenue-growth subscore in the low 40s. The reported operating margin was flat at zero, which generated the strongest fundamental subscore in the upper 70s, but that measure does not override an approximately $11.5 million net loss and roughly $10.2 million EBITDA loss. A cash-burn ratio above 153 and a cash-runway subscore of 15 reinforce the stretched classification, while the reported market capitalization of about $66,700 yielded no contribution from the size tier. Primary regulatory filings show no identified filing date and no recorded events across either the latest 90-day or 180-day periods, leaving cadence at 25. No enforcement hits support the regulatory pillar’s relative strength. Institutional pricing feeds provide no available quote, licensed fundamentals data anchors the financial assessment, and CIN newsroom coverage shows no recent activity.

The forward case rests on regulatory execution because that pillar already carries the highest score and the strongest underlying driver. Continued absence of enforcement hits preserves the 80 enforcement subscore, but rating expansion requires visible filing activity to lift the weak cadence component and validate sustained corporate reporting. Better filing continuity could strengthen confidence without relying on unavailable market pricing or inactive editorial signals, while any accompanying fundamental update would clarify whether revenue contraction and losses are stabilizing. The single most important signal to watch is the appearance of a current primary regulatory filing that restores measurable cadence.